Slide 1: Crescent Biopharma Overview
January 2025 Crescent Biopharma Overview
Slide 2: Disclaimer
2 Disclaimer This presentation is for informational purposes only and only a summary of certain information related to the Company . It does not purport to be complete and does not contain all information that an investor may need to consider in making an investment decision . The information contai
Slide 3: Crescent Biopharma aims to advance the next wave of innovation in cancer therapy
3 Crescent Biopharma aims to advance the next wave of innovation in cancer therapy Potential Indications Stage MoA Program Clinical IND - enabling Discovery NSCLC, other solid tumors 4Q25 2 PD - 1 x VEGF (same cooperative MoA as ivonescimab) CR - 001 1 Solid tumors Mid - 26 Undisclosed #1 (ADC, Topo
Slide 4: Crescent is advancing three highly impactful oncology programs with best-in-class potential
4 Crescent is advancing three highly impactful oncology programs with best - in - class potential CR - 001 PD - 1 x VEGF cooperative tetravalent bsAb; same MoA as ivonescimab CR - 002 & CR - 003 ADCs with topoisomerase inhibitor payloads; potentially best - in - class • Designed to reproduce ivonesc
Slide 5: Multiple ways to win: pipeline enables optionality with combination therapies
5 Multiple ways to win : Crescent pipeline enables optionality with differentiating combination therapies Optimized Novel Monotherapies Synergistic Combination Approaches CR - 001 CR - 002 CR - 003 CR - 001 + CR - 002 CR - 001 + CR - 003 Engineered for: Best - in class efficacy Pharmacokinetics Stab
Slide 6: Crescent leverages two key advances in oncology for next-generation combinations
6 Crescent leverages two key advances in oncology for next - generation combinations within unique portfolio IMMUNO - ONCOLOGY CHEMOTHERAPY Enhanced efficacy & safety via cooperativity Enhanced efficacy & safety via targeting Systemic chemo ADC PD - (L)1 Two revolutions underway in oncology: • Immun
Slide 7: PD-(L)1-targeted therapies have transformed oncology
7 PD - (L)1 - targeted therapies, annualizing $50B+, have transformed oncology – with Keytruda now the best - selling drug in the world Notes: 1. 5 - year follow up demonstrated mOS of 22.0 vs 10.6 months. NSQ: Non - squamous. NSCLC: Non - small cell lung cancer. mOS: m edian overall survival. Sourc
Slide 8: Ivonescimab doubled progression-free survival vs. Keytruda in a Phase 3 NSCLC trial
8 Ivonescimab, a cooperative PD - 1 x VEGF bispecific, doubled progression - free survival vs. Keytruda in a P3 NSCLC trial Notes: HR: hazard ratio. PFS: progression - free survival. AE: adverse event. NSQ: Non - squamous SQ: Squamous. Akeso has licensed i vonescimab to Summit in North America, Sout
Slide 9: Cooperative, tetravalent x VEGF bispecific antibody
9 CR - 001 Cooperative, tetravalent PD - 1 x VEGF bispecific antibody
Slide 10: Ivonescimab's novel, cooperative MoA hypothesized to drive enhanced anti-tumor activity
10 x Cooperativity : VEGF binding to i vonescimab increases affinity to PD - 1 and vice versa , enhancing both T - cell activation and VEGF - signaling blockade . This helps explain the cross - trial outperformance of ivonescimab vs. an anti - PD - L1 + anti - VEGF combination. x Tumor targeting : P
Slide 11: Highly potent x VEGF bsAb designed to recapitulate ivonescimab's cooperative pharmacology
11 CR - 001 is a highly potent PD - 1 x VEGF bsAb designed to recapitulate ivonescimab’s cooperative pharmacology Designed to match ivonescimab PK • Native FcRn binding to match distribution and elimination of ivonescimab Effector - null human IgG Fc • Equivalent to ivonescimab • ADCC carries additi
Slide 12: Replicates ivonescimab's cooperative effect in presence of VEGF
12 CR - 001 replicates ivonescimab’s cooperative effect, with greater binding to and inhibition of PD - 1 signaling in presence of VEGF Notes: Ivonescimab generated internally based on published sequence. PD - 1 / PD - L1 signaling inhibition measured in RLU (relative light units), a measure of lumi
Slide 13: Replicating ivonescimab's tetravalent format requires complex protein engineering
13 Replicating ivonescimab’s tetravalent format and cooperativity, with stable scFvs, requires complex protein engineering Ivonescimab’s unique structure and geometry – and resulting cooperative function – is challenging to replicate ; alternative constructs risk not reproducing ivonescimab’s superi
Slide 14: Potential to transform SoC across a multitude of oncology indications
14 CR - 001 has potential to transform SoC across a multitude of oncology indications, with numerous first - in - class opportunities Notes: EGFRm = mutant epidermal growth factor receptor. Sources: Keytruda Label; Opdivo Label; Tecentriq Label; Imfinzi Label; Libtayo Label; Bavencio Label; Jemperli
Slide 15: Late-stage competitor development programs and timing
15 Timing Phase Combo Population Indication Program Company 2028 2027 2026 2025 3 None 1L PD - L1+ mNSCLC Ivonescimab (China / Australia) 3 Chemo 1L squamous 3 Chemo 1L NSQ & SQ mNSCLC Ivonescimab (Global) 3 None 1L PD - L1+* Multiple global Phase 2/3s and Phase 3s planned between Summit, BioNTech,
Slide 16: Parallel clinical development paths offer first-in-class and lower risk opportunities
16 Parallel clinical development paths offer potential for both first - in - class and lower risk opportunities for CR - 001 Focus on potential first - in - class opportunities with rapid path to market (i.e., efficient development strategy, anticipated likelihood of PFS and OS success ) • Numerous
Slide 17: Phase 1 interim proof-of-concept data are a potentially significant value-generating event
17 Phase 1 interim proof - of - concept data are a potentially significant value - generating event for CR - 001. • Preliminary data from early Phase 1 cohorts provide substantial validation of program because CR - 001’s structural design and preclinical data are similar to ivonescimab. • Early Phas
Slide 18: Scarcity of known constructs with ivonescimab-like cooperative pharmacology
18 • Anti - PD - L1 IgG , with enhanced ADCC • VEGF trap Scarcity of known constructs with potential to exhibit ivonescimab - like cooperative pharmacology and design Sources: Internal data; Summit Therapeutics 2023 SITC Poster; BioNTech 2024 ESMO Presentation; LaNova patent filings; Various pa tent
Slide 19: Preclinical data reproduce ivonescimab's pharmacology and are rapidly advancing
19 CR - 001 preclinical data reproduce ivonescimab’s breakthrough pharmacology & are rapidly advancing to generate significant value Unprecedented third - party data validate PD - 1 x VEGF cooperativity Transformative MoA for $50B+ market CR - 001’s proprietary engineering is designed to replicate i
Slide 20: CR-002 & CR-003: Topoisomerase inhibitor ADCs against validated targets
20 CR - 002 & CR - 003 Topoisomerase inhibitor ADCs against validated targets
Slide 21: CR-002 and CR-003 are potentially best-in-class topoisomerase inhibitor ADCs
21 CR - 002 and CR - 003 are potentially best - in - class topoisomerase inhibitor ADCs, with applicability across solid tumors Best - in - modality topoisomerase inhibitor payloads • Topoisomerase inhibitor payloads have consistently demonstrated superior efficacy and safety over microtubule inhibi
Slide 22: ADCs with topoisomerase inhibitor payloads have demonstrated best-in-modality efficacy and safety
22 ADCs with topoisomerase inhibitor payloads have demonstrated best - in - modality efficacy and safety Notes: NSCLC = non - small cell lung cancer; GEJ = gastroesophageal junction; A = approved; R = in registration. PN rates are weig hted averages, by number of patients, across indications / trial
Slide 23: Corporate
23 Corporate
Slide 24: Rapidly growing leadership team with deep experience
24 Rapidly growing leadership team with deep experience building the next generation of biotechnology companies Jonathan Violin Interim CEO Board of Directors Chris Doughty Chief Business Officer Peter Harwin Board of Directors Alex Balcom Board of Directors Susan Moran Board of Directors
Slide 25: Anticipated catalysts and key external events
25 2H: Initial clinical data CR - 001 (cooperative PD - 1 x VEGF bsAb) Mid - year: IND 2H: DC CR - 002 (undisclosed, ADC #1 with TopoI payload) 1H: DC CR - 003 (undisclosed, ADC #2 with TopoI payload) Multiple P3 trials ongoing or planned (e.g., SCLC, TNBC, NSCLC) , with numerous PFS & OS readouts e
Slide 26: Estimated capitalization following close of transactions
26 Estimated capitalization following close of transactions Estimated total shares of common stock of the combined company post - closing 2,081,292,577 Shares on an as - converted basis 64,532,953 • Shares of common stock outstanding GlycoMimetics • Shares of common stock outstanding 105,137,814 Cre
Slide 27: Thank you
Thank you